Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) insider Aradhana Sarin sold 578 shares of the company’s stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $132.00, for a total transaction of $76,296.00. Following the transaction, the insider now owns 30,201 shares in the company, valued at approximately $3,986,532. The sale was disclosed in a filing with the SEC, which is available at this link.
NASDAQ:ALXN opened at $125.34 on Thursday. The stock has a 50-day simple moving average of $124.39. The company has a current ratio of 3.87, a quick ratio of 3.36 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $28.06 billion, a P/E ratio of 17.68, a P/E/G ratio of 0.94 and a beta of 1.58. Alexion Pharmaceuticals, Inc. has a twelve month low of $92.56 and a twelve month high of $141.86.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.99 by $0.40. The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.13 billion. Alexion Pharmaceuticals had a net margin of 9.59% and a return on equity of 19.53%. The company’s revenue for the quarter was up 22.5% on a year-over-year basis. During the same period last year, the firm posted $1.68 earnings per share. As a group, analysts expect that Alexion Pharmaceuticals, Inc. will post 8.61 earnings per share for the current year.
A number of research analysts have issued reports on the stock. Raymond James assumed coverage on shares of Alexion Pharmaceuticals in a research note on Wednesday, April 10th. They set an “outperform” rating and a $161.00 price target on the stock. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 1st. Royal Bank of Canada restated an “outperform” rating and set a $186.00 price target (up previously from $165.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, March 27th. Cowen restated a “buy” rating and set a $165.00 price target on shares of Alexion Pharmaceuticals in a research note on Wednesday, March 13th. Finally, TheStreet upgraded shares of Alexion Pharmaceuticals from a “c” rating to a “b” rating in a research note on Thursday, April 25th. Six research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $161.06.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Read More: Trading Ex-Dividend
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.